This site is intended for
Influenza Vaccine Offers Cardiovascular Benefits in Individuals at Varying Cardiovascular Risk
- Influenza vaccine was associated with a lower risk of cardiovascular (CV) events, irrespective of the underlying CV risk.
Why This Matters
- Findings suggest that improved vaccine uptake may help reduce the risk of first acute CV events in people who are already eligible to receive the seasonal influenza vaccine.
- The observational study included 193,900 participants (age 40-84 years) with a first acute CV event using linked data from the UK Clinical Practice Research Datalink, Hospital Episode Statistics Admitted Patient Care, and Office for National Statistics (2009-2019).
- Primary outcome: any CV event (myocardial infarction, unstable angina, acute left ventricular heart failure, stroke, transient ischaemic attack, or acute limb ischaemia).
- Secondary outcomes: individual CV events except acute limb ischaemia.
- Funding: Wellcome Trust.
- Overall, 105,539 participants had hypertension and 172,050 had a QRISK2 score of ≥10%.
- There was a significant reduction in the risk of acute CV events in the 15-28 days post-vaccination (incidence ratio [IR] 0.72; 95% CI 0.70 to 0.74).
- These effects tapered but remained significant in the 91-120 days post-vaccination (IR 0.84; 95% CI 0.82 to 0.85).
- A significant reduction was obseved in individual CV events, but the reduction was more significant in myocardial infarction than other CV events (15-28 days: IR 0.60; 95% CI 0.57 to 0.64).
- The risk of acute CV events significantly reduced post-vaccination among individuals across all age groups and with raised and lower CV risk.
- Observational design.
- Risk of confounding.